Abstract
Systemic juvenile idiopathic arthritis (sJIA) is the most severe variant of JIA that can be characterized by a life-threatening course. sJIA manifests with fever, arthralgia/arthritis, hepatosplenomegaly, leukocytosis and systemic inflammation markers. Macrophage activation syndrome (MAS) is the most severe complication of this disease. This Article represents up-to-date information on pathogeneses of sJIA and MAS, describes approaches to diagnosis, treatment of both uncomplicated and complicated forms of sJIA and refractory variants of the MAS course. Current data regarding the monitoring of sJIA therapy effectiveness and safety is presented as well. Predictors for the most recently discovered, i.e. relatively new “target organs” in patients with sJIA and cardiopulmonary disorders in particular are given.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
